[{"id":"b75ecd93-1120-4cfc-9f9a-b68e1481f48d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05588141","created_at":"2022-10-20T14:11:44.038Z","updated_at":"2025-02-25T12:29:09.098Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations","source_id_and_acronym":"NCT05588141","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zotiraciclib (TG02)"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 05/16/2023","start_date":" 05/16/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/02/2029","study_completion_date":" 08/02/2029","last_update_posted":"2025-02-24"},{"id":"21be25ed-db5c-4f88-af53-6dabef3b154a","acronym":"SUMIT-ELA","url":"https://clinicaltrials.gov/study/NCT05963997","created_at":"2023-07-27T17:09:07.832Z","updated_at":"2025-02-25T13:41:37.681Z","phase":"Phase 1/2","brief_title":"A Study of Samuraciclib and Elacestrant in Participants with Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer","source_id_and_acronym":"NCT05963997 - SUMIT-ELA","lead_sponsor":"Carrick Therapeutics Limited","biomarkers":" HER-2 • ER • TP53 • CDK4","pipe":" | ","alterations":" TP53 mutation • ER positive • HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation","tags":["HER-2 • ER • TP53 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ER positive • HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orserdu (elacestrant) • samuraciclib (CT7001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 10/09/2023","start_date":" 10/09/2023","primary_txt":" Primary completion: 12/23/2025","primary_completion_date":" 12/23/2025","study_txt":" Completion: 12/23/2025","study_completion_date":" 12/23/2025","last_update_posted":"2025-02-21"},{"id":"3f832c54-ae2b-45dd-b72a-df4624a79314","acronym":"SUMIT-BC","url":"https://clinicaltrials.gov/study/NCT05963984","created_at":"2023-07-27T17:09:07.566Z","updated_at":"2025-02-25T13:41:37.189Z","phase":"Phase 2","brief_title":"A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants","source_id_and_acronym":"NCT05963984 - SUMIT-BC","lead_sponsor":"Carrick Therapeutics Limited","biomarkers":" HER-2 • ER • TP53 • CDK4","pipe":" | ","alterations":" TP53 mutation • ER positive • HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER • TP53 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ER positive • HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • samuraciclib (CT7001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/14/2023","start_date":" 12/14/2023","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-21"},{"id":"8ce17564-4a45-43a3-9a95-423caa8fe9c6","acronym":"KEYNOTE-E45","url":"https://clinicaltrials.gov/study/NCT05394103","created_at":"2022-05-27T12:55:37.575Z","updated_at":"2025-02-25T16:17:45.159Z","phase":"Phase 1/2","brief_title":"Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors","source_id_and_acronym":"NCT05394103 - KEYNOTE-E45","lead_sponsor":"Qurient Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • mocaciclib (Q901)"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 08/30/2022","start_date":" 08/30/2022","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 08/30/2026","study_completion_date":" 08/30/2026","last_update_posted":"2024-03-12"},{"id":"cb41102b-0fb2-48d9-9bc0-4853a675d51c","acronym":"ELUCIDATE","url":"https://clinicaltrials.gov/study/NCT05985655","created_at":"2023-08-14T16:10:12.231Z","updated_at":"2024-07-02T16:35:16.495Z","phase":"Phase 1/2","brief_title":"Study to Assess GTAEXS617 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05985655 - ELUCIDATE","lead_sponsor":"Exscientia AI Limited","biomarkers":" HER-2 • CDK6 • CD4","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • CDK6 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e REC-617"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 07/06/2023","start_date":" 07/06/2023","primary_txt":" Primary completion: 01/01/2028","primary_completion_date":" 01/01/2028","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2024-03-05"},{"id":"1fd1e036-0ccd-44f6-a252-1fd3373b58b2","acronym":"CT7001_001","url":"https://clinicaltrials.gov/study/NCT03363893","created_at":"2021-01-18T16:36:10.643Z","updated_at":"2024-07-02T16:35:25.323Z","phase":"Phase 1/2","brief_title":"Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies","source_id_and_acronym":"NCT03363893 - CT7001_001","lead_sponsor":"Carrick Therapeutics Limited","biomarkers":" HER-2 • ER","pipe":"","alterations":" ","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • samuraciclib (CT7001)"],"overall_status":"Completed","enrollment":" Enrollment 124","initiation":"Initiation: 11/14/2017","start_date":" 11/14/2017","primary_txt":" Primary completion: 12/15/2022","primary_completion_date":" 12/15/2022","study_txt":" Completion: 12/15/2022","study_completion_date":" 12/15/2022","last_update_posted":"2023-12-22"},{"id":"23cc0738-3191-4a02-95c6-0041a5970bd6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05866692","created_at":"2023-05-19T13:04:54.015Z","updated_at":"2024-07-02T16:35:30.316Z","phase":"Phase 1","brief_title":"A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05866692","lead_sponsor":"TYK Medicines, Inc","biomarkers":" HER-2 • PD-L1 • KRAS • ER • BRCA","pipe":" | ","alterations":" KRAS mutation • HER-2 negative • ER negative • BRCA mutation • PGR expression","tags":["HER-2 • PD-L1 • KRAS • ER • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • HER-2 negative • ER negative • BRCA mutation • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TY-2699a"],"overall_status":"Recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 08/17/2023","start_date":" 08/17/2023","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2023-11-06"},{"id":"008ac45d-42cf-420e-ad02-8925f15a65fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04247126","created_at":"2021-01-18T20:38:36.579Z","updated_at":"2024-07-02T16:35:31.331Z","phase":"Phase 1","brief_title":"A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors","source_id_and_acronym":"NCT04247126","lead_sponsor":"Syros Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • fulvestrant • SY-5609"],"overall_status":"Completed","enrollment":" Enrollment 105","initiation":"Initiation: 01/23/2020","start_date":" 01/23/2020","primary_txt":" Primary completion: 01/31/2023","primary_completion_date":" 01/31/2023","study_txt":" Completion: 03/30/2023","study_completion_date":" 03/30/2023","last_update_posted":"2023-10-27"},{"id":"09433bad-7c17-41a7-b1ca-4ac19bbc5a86","acronym":"STEAM","url":"https://clinicaltrials.gov/study/NCT03224104","created_at":"2021-01-18T15:54:47.667Z","updated_at":"2024-07-02T16:36:09.663Z","phase":"Phase 1","brief_title":"Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma","source_id_and_acronym":"NCT03224104 - STEAM","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" IDH1 • IDH2 • MCL1 • CDK9","pipe":" | ","alterations":" IDH1 R132H • IDH1 R132","tags":["IDH1 • IDH2 • MCL1 • CDK9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132H • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • zotiraciclib (TG02)"],"overall_status":"Completed","enrollment":" Enrollment 71","initiation":"Initiation: 06/12/2018","start_date":" 06/12/2018","primary_txt":" Primary completion: 05/05/2022","primary_completion_date":" 05/05/2022","study_txt":" Completion: 05/05/2022","study_completion_date":" 05/05/2022","last_update_posted":"2022-05-31"},{"id":"c888a839-4434-4bf4-97af-0865b3e560f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT00999401","created_at":"2021-01-18T03:54:26.432Z","updated_at":"2024-07-02T16:36:19.263Z","phase":"Phase 1","brief_title":"A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT00999401","lead_sponsor":"Cyclacel Pharmaceuticals, Inc.","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sapacitabine (CYC682) • seliciclib (CYC202)"],"overall_status":"Completed","enrollment":" Enrollment 103","initiation":"Initiation: 04/01/2009","start_date":" 04/01/2009","primary_txt":" Primary completion: 07/16/2019","primary_completion_date":" 07/16/2019","study_txt":" Completion: 08/13/2019","study_completion_date":" 08/13/2019","last_update_posted":"2021-12-22"},{"id":"9c28c66f-c3b4-4633-96d1-74a5ed78d628","acronym":"","url":"https://clinicaltrials.gov/study/NCT02942264","created_at":"2021-01-18T14:26:49.487Z","updated_at":"2024-07-02T16:36:23.846Z","phase":"Phase 2","brief_title":"Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma","source_id_and_acronym":"NCT02942264","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • ATRX","pipe":"","alterations":" ","tags":["TP53 • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • zotiraciclib (TG02)"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 12/14/2016","start_date":" 12/14/2016","primary_txt":" Primary completion: 08/26/2020","primary_completion_date":" 08/26/2020","study_txt":" Completion: 08/26/2020","study_completion_date":" 08/26/2020","last_update_posted":"2021-09-28"}]